scholarly journals Tackling HLA Deficiencies Head on with Oncolytic Viruses

Cancers ◽  
2021 ◽  
Vol 13 (4) ◽  
pp. 719
Author(s):  
Kerry Fisher ◽  
Ahmet Hazini ◽  
Leonard W. Seymour
Keyword(s):  
Human Leukocyte Antigen ◽  
Cancer Patients ◽  
Treatment Approach ◽  
Human Leukocyte ◽  
Oncolytic Viruses ◽  
Immune Competence ◽  
Leukocyte Antigen ◽  
Immunological Responses ◽  
Therapeutic Outcomes ◽  
Hla Phenotype

Dysregulation of HLA (human leukocyte antigen) function is increasingly recognized as a common escape mechanism for cancers subject to the pressures exerted by immunosurveillance or immunotherapeutic interventions. Oncolytic viruses have the potential to counter this resistance by upregulating HLA expression or encouraging an HLA-independent immunological responses. However, to achieve the best therapeutic outcomes, a prospective understanding of the HLA phenotype of cancer patients is required to match them to the characteristics of different oncolytic strategies. Here, we consider the spectrum of immune competence observed in clinical disease and discuss how it can be best addressed using this novel and powerful treatment approach.

scholarly journals Human Leukocyte Antigen-G (HLA-G) Polymorphism and Expression in Breast Cancer Patients

PLoS ONE ◽  
2014 ◽  
Vol 9 (5) ◽  
pp. e98284 ◽  
Author(s):  
Seri Jeong ◽  
Seho Park ◽  
Byeong-Woo Park ◽  
Younhee Park ◽  
Oh-Joong Kwon ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Human Leukocyte Antigen ◽  
Cancer Patients ◽  
Human Leukocyte ◽  
Breast Cancer Patients ◽  
Leukocyte Antigen ◽  
Human Leukocyte Antigen G

Is the survival of melanoma patients receiving polyvalent melanoma cell vaccine linked to the human leukocyte antigen phenotype of patients?

1998 ◽  
Vol 16 (4) ◽  
pp. 1430-1437 ◽  
Author(s):  
D S Hoon ◽  
T Okamoto ◽  
H J Wang ◽  
R Elashoff ◽  
A J Nizze ◽  
...  
Keyword(s):  
Overall Survival ◽  
Human Leukocyte Antigen ◽  
Melanoma Cell ◽  
Human Leukocyte ◽  
Hla Class I ◽  
Class I ◽  
Cell Vaccine ◽  
Leukocyte Antigen ◽  
Hla Phenotype ◽  
Melanoma Patients

PURPOSE An allogeneic polyvalent melanoma cell vaccine (PMCV) has been shown to be efficacious in improving overall survival of patients with malignant melanoma in a phase II clinical setting. The PMCV consists of three allogeneic melanoma cell lines. The objectives of the study were to determine (1) whether the survival of melanoma patients who received PMCV was related to the patient's human leukocyte antigen (HLA) class I phenotype matching the HLA class I phenotype of the PMCV, and (2) whether PMCV clinical efficacy was correlated to melanoma patients with a particular HLA phenotype(s). MATERIALS AND METHODS PMCV was given to 69 melanoma patients with American Joint Committee on Cancer (AJCC) stage I to IV disease status. The PMCV and patients lymphocytes were typed for HLA-A and -B. A correlation was made between the HLA expression of PMCV lines and the HLA of patients to their survival status. A second correlation was made between the HLA of patients and survival independent of the PMCV HLA phenotype. RESULTS Patients whose HLA phenotype (A3/11 and B7/44) matched the PMCV lines had a better overall survival (P < .029). Analysis of HLA expression of patients independent of PMCV HLA to survival showed that HLA-A25 phenotype patients had a significantly better overall survival (P = .006). HLA-B35 patients had a poorer survival outcome (P = .019). CONCLUSION The studies indicate that overall survival following PMCV treatment in melanoma patients significantly correlates with their HLA phenotypes. These correlations may be related to the host immune response to the PMCV or due to differences in the clinical course of melanoma in patients with different HLA types.

Association of human leukocyte antigen groups with oral mucositis in patients undergoing bone marrow transplantation

2020 ◽  
Author(s):  
Ayse Nur Tufan ◽  
Fatma Savran Oguz ◽  
Fatih Tufan ◽  
Cigdem Kekik ◽  
Fatma Bilgin Tarakci ◽  
...  
Keyword(s):  
Stem Cell ◽  
Human Leukocyte Antigen ◽  
Oral Mucositis ◽  
Conditioning Regimen ◽  
Human Leukocyte ◽  
Leukocyte Antigen ◽  
Stem Cell Source ◽  
Hematopoetic Stem Cell ◽  
Hla Phenotype

Abstract Background: Oral mucositis (OM) after hematopoetic stem cell transplantation (HSCT) may lead to toxicity that impair quality of life. Associations between some diseases and human leukocyte antigen (HLA) groups have been long recognized. A genetic contribution as the association of HLA groups with OM after HSCT, has not been reported to date. We aimed to assess whether an association of HLA phenotype and OM after allogeneic HSCT exists.Methods: This was a prospective observational study in which OM was assessed with clinical questioning and examination. Association of OM with gender, age, HLA phenotypes, diagnosis, conditioning regimen, stem cell source, engraftment times, and complications was investigated.Results: 45 patients were enrolled. All the patients with HLA-B44 phenotype developed mild OM, while all patients with HLA-DR15 phenotype developed severe OM. HLA-A23, HLA-B21, HLA-B44, HLA-DR15, and HLA-DR11 were associated with shorter OM duration. HLA-A26 and HLA-B52 were associated with longer OM duration. Myeloablative conditioning regimen and longer duration of neutropenia were associated with longer OM duration. Regression analysis revealed HLA-B44 and HLA-DR11 as independent factors associated with milder OM.Conclusion: We identified that some HLA alleles correlated with OM severity and duration. These findings may facilitate predicting risk of morbidity and may provide incorporation of individualized preventive and treatment approaches.

Sign in / Sign up

Export Citation Format

Share Document